

Product Information

Anti-Transforming Growth Factor- β 3

produced in goat, affinity isolated antibody

Catalog Number **T4692**

Product Description

Anti-Transforming Growth Factor- β 3 is produced in goat with purified recombinant chicken TGF- β 3 expressed in Sf 21 insect cells as immunogen. The antibody is purified using human TGF- β 3 affinity chromatography.

Anti-Transforming Growth Factor- β 3 (TGF- β 3) will recognize human and chicken TGF- β 3 by various immunochemical techniques including neutralization, immunoblotting, and ELISA. By immunoblotting (non-reducing conditions) and ELISA, the antibody shows less than 25 % cross-reactivity with recombinant amphibian TGF- β 5 and less than 10 % cross-reactivity with TGF- β 1, TGF- β 1.2, and TGF- β 2. This antibody also shows less than 5 % cross-reactivity with recombinant human LAP (latency associated peptide, TGF- β 1).

Transforming Growth Factor- β 5 (TGF- β 5) is a member of the TGF- β family of growth factors. The TGF- β polypeptides are multifunctional; capable of influencing cell proliferation, differentiation, and other functions in a wide range of cell types. Transformed, as well as non-neoplastic tissues, release transforming growth factors; and essentially all mammalian cells possess a specific TGF receptor.¹ The multi-modal nature of TGF- β is seen in its ability to stimulate or inhibit cellular proliferation. In general, cells of mesenchymal origin appear to be stimulated by TGF- β whereas cells of epithelial or neuroectodermal origin are inhibited by the peptide.^{2,3}

A high level of TGF- β 3 in normal adult heart, lung, and brain suggests a possible role for this factor in the regulation of a variety of normal physiological functions. The expression of TGF- β 3 in different locations and at specific stages of embryogenesis suggests its involvement in the regulation of development. Similar to the other isoforms of TGF- β , the upregulated activation of TGF- β 3 might also be involved in a variety of pathological conditions. TGF- β 3 has been detected

in human, porcine, and avian sources and is expressed in cells of mesenchymal origin, suggesting a different role for this protein than for TGF- β 1 or TGF- β 2. TGF- β 3 is less prevalent in natural expression than either TGF- β 1 or TGF- β 2, but is the most abundant mRNA expressed in chick embryos.⁴ It is also expressed in human umbilical cord and in several human carcinoma cells.

Reagent

Supplied lyophilized from a 0.2 μ m filtered solution of phosphate buffered saline with 5% trehalose.

Preparation Instructions

To one vial of lyophilized powder, add 0.5 mL of 0.2 μ m-filtered phosphate buffered saline (PBS) to produce a 0.2 mg/ml stock solution of Anti-TGF- β 3.

Storage/Stability

Prior to reconstitution, store at -20°C . Reconstituted product may be stored at $2-8^{\circ}\text{C}$ for up to one month. For prolonged storage, freeze in working aliquots at -20°C . Avoid repeated freezing and thawing. Do not store in frost-free freezer.

Product Profile

The Neutralization Dose₅₀ (ND₅₀) for Anti-TGF- β 3 is 0.01-0.05 $\mu\text{g/ml}$ in the presence of 0.1 ng/mL recombinant human TGF- β 3 and 7.5 ng/mL recombinant mouse IL-4, using the human HT-29 colon adenocarcinoma cell line.

The ND₅₀ of this antibody is defined as the concentration of antibody resulting in a one-half maximal inhibition of bioactivity of TGF- β 3 that is present at a concentration just high enough to elicit a maximum response.

The exact concentration of antibody required to neutralize TGF- β 3 activity is dependent on the cytokine concentration, cell type, growth conditions, and the type of activity studied.

Immunoblotting: a working concentration of 0.1 µg/mL antibody is recommended.

Immunohistochemistry: a working concentration of 5-15 µg/mL antibody is recommended. The detection limit for TGF-β3 is ~0.6 ng/well.

Note: In order to obtain best results in different techniques and preparations we recommend determining optimal working dilutions by titration test.

Endotoxin level is < 0.10 EU/µg antibody as determined by the LAL (Limulus amebocyte lysate) method.

References

1. Sporn, M., et al., *Science*, **233**, 532 (1986).
2. Moses, H., et al., *Cancer Cells*, Vol. 3, Feramisco, J., et al., (eds.), Cold Spring Harbor, New York (1985).
3. Hayashi, I., and Carr, B., *J. Cell Physiology*, **125**, 82 (1985).
4. Roberts, A., and Sporn, J., *Peptide Growth Factors and their Receptors I*, Sporn M., and Roberts, A., (eds.), Springer-Verlag, New York (1991).

ADM,PHC 08/11-1